This page shows the latest Santaris news and features for those working in and with pharma, biotech and healthcare.
These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing
Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing
Roche's return to the field of RNAi research looks to be complete, following its $450m deal to acquire Denmark's Santaris Pharma. ... The deal is expected to close later this month, when Santaris' Danish operations will become the Roche Innovation Center
Agrees option with Santaris to nominate additional discovery targets. Shire has expanded its rare genetic disease alliance with Danish biopharmaceutical company Santaris. ... The Danish clinical stage biopharmaceutical company's president and CEO Henrik
ALN-RSV01. Alnylam. RSV. respiratory syncytial virus infection. IIb. miravirsen (SPC3649). Santaris Pharma. ... I. EZN-3042. Santaris Pharma. Survivin. cancer. I. EZN-2968. Santaris Pharma. HIF-1a.
In January, Pfizer extended an existing collaboration with Santaris ($614m) for the 'locked nucleic acid' (LNA) technology for gene-silencing RNA technology. ... Preclinical. 632. Santaris Pharma/Pfizer. Expansion of Locked Nucleic Acid Drug platform
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics.
August also saw Roche's pRED group acquire Santaris Pharma for $450m - $250m upfront and $200m contingent on predetermined research milestones. ... Clearly it has not taken Roche long to be convinced of these claims given its $10m discovery alliance with
Santaris/Roche. Discovery and development. Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform.
Platform technologies. Of the 11 large pharma deals announced in April, 8 involve platform technologies. In addition to those already mentioned are: Ambrx / Astellas; Isis/ Roche; Ra/ Merck; Santaris/ Bristol-Myers ... Santaris/ BMS. April also saw
199. Velcera/ Perrigo Company. Acquisition. Pet health products. 160. Santaris Pharma/ BMS.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co and Sandoz Pharma.
the recent purchase of Virophama and an alliance agreed last year with Santaris.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.